McKesson Corporation58155Q103US58155Q103107/30/2025Advisory Vote to Approve the Company's Executive CompensationSECTION 14A SAY-ON-PAY VOTES97498.0000000FOR97498.000000FORVerona Pharma Plc925050106US925050106409/24/2025To approve, on an advisory, non-binding basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the Transaction, as disclosed in the table entitled "Potential Payments to Named Executive Officers" beginning on page 70 of the proxy statement, including the associated narrative discussion, and the agreements or understandings pursuant to which such compensation may be paid or become payable.SECTION 14A SAY-ON-PAY VOTES80416.0000000FOR80416.000000FORMedtronic plcG5960L103IE00BTN1Y11510/16/2025Approving, on an advisory basis, the Company's executive compensation;SECTION 14A SAY-ON-PAY VOTES18576.0000000FOR18576.000000FORRezolute, Inc.76200L309US76200L309611/19/2025To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES346837.0000000AGAINST346837.000000AGAINSTMerus N.V.N5749R100NL001160626412/09/2025Non-binding advisory proposal to approve certain compensation arrangementsSECTION 14A SAY-ON-PAY VOTES130742.0000000AGAINST130742.000000AGAINSTThe Cooper Companies, Inc.216648501US216648501904/07/2026Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES79565.0000000FOR79565.000000FORHCA Healthcare, Inc.40412C101US40412C101804/23/2026Advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES4.0000000FOR4.000000FORIntuitive Surgical, Inc.46120E602US46120E602304/30/2026To approve, by advisory vote, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES1056.0000000FOR1056.000000FOREli Lilly and Company532457108US532457108305/04/2026Approval, on an advisory basis, of the compensation paid to the company's named executive officers.SECTION 14A SAY-ON-PAY VOTES52326.0000000FOR52326.000000FORAcadia Healthcare Company, Inc.00404A109US00404A109705/06/2026Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES575130.0000000FOR575130.000000FORAmneal Pharmaceuticals, Inc.03168L105US03168L105205/06/2026Advisory vote to approve executive compensation.SECTION 14A SAY-ON-PAY VOTES544815.0000000FOR544815.000000FORPenumbra, Inc.70975L107US70975L107005/06/2026To approve, on a non-binding, advisory basis, the compensation that Penumbra's named executive officers will or may be eligible to receive in connection with the Merger; andSECTION 14A SAY-ON-PAY VOTES124152.0000000FOR124152.000000FORStryker Corporation863667101US863667101305/06/2026Advisory Vote to Approve Named Executive Officer Compensation.SECTION 14A SAY-ON-PAY VOTES15888.0000000FOR15888.000000FOREdwards Lifesciences Corporation28176E108US28176E108205/07/2026Advisory Vote to Approve Named Executive Officer CompensationSECTION 14A SAY-ON-PAY VOTES224128.0000000FOR224128.000000FORAbivax SA00370M103US00370M103605/11/2026Approve Compensation of Sylvie Gregoire, Chairwoman of the BoardSECTION 14A SAY-ON-PAY VOTES22988.0000000AGAINST22988.000000AGAINSTAbivax SA00370M103US00370M103605/11/2026Approve Compensation of Marc de Garidel, CEOSECTION 14A SAY-ON-PAY VOTES22988.0000000AGAINST22988.000000AGAINSTCentene Corporation15135B101US15135B101705/12/2026ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.SECTION 14A SAY-ON-PAY VOTES228095.0000000FOR228095.000000FORPersonalis, Inc.71535D106US71535D106305/12/2026Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES758938.0000000FOR758938.000000FORIndivior Pharmaceuticals, Inc.45579U109US45579U109705/13/2026To approve, on an advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES123219.0000000FOR123219.000000FORIndivior Pharmaceuticals, Inc.45579U109US45579U109705/13/2026To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES123219.0000000ONE YEAR123219.000000FORViking Therapeutics, Inc.92686J106US92686J106005/19/2026TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.SECTION 14A SAY-ON-PAY VOTES15858.0000000AGAINST15858.000000AGAINSTAlign Technology, Inc.016255101US016255101605/20/2026Advisory Vote to Approve the Compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTES7919.0000000FOR7919.000000FORInteger Holdings Corporation45826H109US45826H109505/20/2026To approve, in an advisory non-binding vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES116322.0000000FOR116322.000000FORThermo Fisher Scientific Inc.883556102US883556102305/20/2026An advisory vote to approve named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES12790.0000000AGAINST12790.000000AGAINSTBrightSpring Health Services, Inc.10950A106US10950A106005/21/2026Advisory vote on executive compensationSECTION 14A SAY-ON-PAY VOTES161796.0000000FOR161796.000000FORDianthus Therapeutics, Inc.252828108US252828108005/21/2026To approve, on an advisory basis, the compensation paid to our named executive officers; andSECTION 14A SAY-ON-PAY VOTES66826.0000000FOR66826.000000FORHenry Schein, Inc.806407102US806407102505/21/2026Proposal to approve, by non-binding vote, the 2025 compensation paid to the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES13144.0000000FOR13144.000000FORIllumina, Inc.452327109US452327109005/21/2026To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES792.0000000FOR792.000000FORNeoGenomics, Inc.64049M209US64049M209805/21/2026Approval, on a non-binding advisory basis, of the Compensation Paid to the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES1542566.0000000FOR1542566.000000FORVera Therapeutics, Inc.92337R101US92337R101405/21/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES77502.0000000FOR77502.000000FORWaters Corporation941848103US941848103505/21/2026To approve, on a non-binding, advisory basis, the compensation of the Company's executive officers.SECTION 14A SAY-ON-PAY VOTES11.0000000FOR11.000000FORCompass Pathways Plc20451W101US20451W101805/27/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2025SECTION 14A SAY-ON-PAY VOTES1183259.0000000FOR1183259.000000FORDexCom, Inc.252131107US252131107405/27/2026To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2025.SECTION 14A SAY-ON-PAY VOTES129610.0000000FOR129610.000000FORNeurocrine Biosciences, Inc.64125C109US64125C109905/27/2026Advisory vote on the compensation paid to the Company's named executive officers;SECTION 14A SAY-ON-PAY VOTES201348.0000000FOR201348.000000FORTenet Healthcare Corporation88033G407US88033G407305/27/2026To vote, on an advisory basis, to approve the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTES395457.0000000FOR395457.000000FORGlaukos Corporation377322102US377322102905/28/2026Approval, on an advisory basis, of the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES178556.0000000FOR178556.000000FORUnitedHealth Group Incorporated91324P102US91324P102106/01/2026Advisory approval of the Company's executive compensation.SECTION 14A SAY-ON-PAY VOTES50115.0000000FOR50115.000000FORKodiak Sciences Inc.50015M109US50015M109906/02/2026Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES84053.0000000FOR84053.000000FOROruka Therapeutics, Inc.687604108US687604108706/02/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES161958.0000000FOR161958.000000FORGlobus Medical, Inc.379577208US379577208206/03/2026Approval, on a non-binding, advisory basis, of the 2025 compensation of the company's named executive officers (the "Say-on-Pay" Vote).SECTION 14A SAY-ON-PAY VOTES70150.0000000FOR70150.000000FORAlignment Healthcare, Inc.01625V104US01625V104406/04/2026Approval, on an non-binding, advisory basis, of the compensation of our Named Executive OfficersSECTION 14A SAY-ON-PAY VOTES18055.0000000FOR18055.000000FORAmylyx Pharmaceuticals, Inc.03237H101US03237H101406/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES6356.0000000AGAINST6356.000000AGAINSTCapricor Therapeutics, Inc.14070B309US14070B309606/04/2026APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTES11733.0000000FOR11733.000000FORCapricor Therapeutics, Inc.14070B309US14070B309606/04/2026APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ONA NON-BINDING ADVISORY BASISSECTION 14A SAY-ON-PAY VOTES11733.0000000ONE YEAR11733.000000FORCG Oncology, Inc.156944100US156944100906/04/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES298.0000000FOR298.000000FORCG Oncology, Inc.156944100US156944100906/04/2026To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES298.0000000ONE YEAR298.000000FOROutset Medical, Inc.690145206US690145206906/04/2026To approve, on a non-binding basis, the 2025 compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES523333.0000000AGAINST523333.000000AGAINSTTango Therapeutics, Inc.87583X109US87583X109006/04/2026To approve, on a non-binding, advisory basis, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES351308.0000000FOR351308.000000FORAxsome Therapeutics, Inc.05464T104US05464T104306/05/2026To approve, by non-binding advisory vote, the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES2617.0000000FOR2617.000000FORTectonic Therapeutic, Inc.878972108US878972108606/08/2026Advisory approval of the compensation of the Company's Named Executive Officers.SECTION 14A SAY-ON-PAY VOTES8887.0000000FOR8887.000000FORPraxis Precision Medicines, Inc.74006W207US74006W207006/10/2026To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.SECTION 14A SAY-ON-PAY VOTES28969.0000000FOR28969.000000FORSyndax Pharmaceuticals, Inc.87164F105US87164F105706/10/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 proxy statement.SECTION 14A SAY-ON-PAY VOTES212687.0000000FOR212687.000000FORuniQure N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES12129.0000000FOR12129.000000FORuniQure N.V.N90064101NL001069665406/10/2026Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company.SECTION 14A SAY-ON-PAY VOTES12129.0000000ONE YEAR12129.000000FORNatera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the compensation of Natera, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES51899.0000000FOR51899.000000FORNatera, Inc.632307104US632307104206/11/2026To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTES51899.0000000ONE YEAR51899.000000FORMirum Pharmaceuticals, Inc.604749101US604749101306/15/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES227.0000000FOR227.000000FORCullinan Therapeutics, Inc.230031106US230031106306/16/2026Proposal to vote, on an advisory basis, to approve our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES178590.0000000FOR178590.000000FORMadrigal Pharmaceuticals, Inc.558868105US558868105706/17/2026Advisory vote to approve executive compensationSECTION 14A SAY-ON-PAY VOTES158.0000000FOR158.000000FORStructure Therapeutics Inc.86366E106US86366E106406/17/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES49537.0000000FOR49537.000000FORPenumbra, Inc.70975L107US70975L107006/18/2026To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES124152.0000000FOR124152.000000FORRevolution Medicines, Inc.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTES91023.0000000FOR91023.000000FORBridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.SECTION 14A SAY-ON-PAY VOTES1589.0000000FOR1589.000000FORBridgeBio Pharma, Inc.10806X102US10806X102806/22/2026To conduct a non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.SECTION 14A SAY-ON-PAY VOTES1589.0000000ONE YEAR1589.000000FORCelldex Therapeutics, Inc.15117B202US15117B202506/25/2026To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.SECTION 14A SAY-ON-PAY VOTES354433.0000000FOR354433.000000FORTarsus Pharmaceuticals, Inc.87650L103US87650L103506/25/2026To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.SECTION 14A SAY-ON-PAY VOTES69395.0000000FOR69395.000000FORUnited Therapeutics Corporation91307C102US91307C102706/26/2026Advisory resolution to approve executive compensation.SECTION 14A SAY-ON-PAY VOTES10161.0000000FOR10161.000000FOR